← Human Trials & Peer-Reviewed Studies
Regulation of faecal biomarkers in inflammatory bowel disease patients treated with oral mastiha (Pistacia lentiscus) supplement: A double-blind and placebo-controlled randomised trial.
Plain-language guide to PMID 30450689 (2019): double-blind randomized controlled trial of Copper (Supplement) in 60 patients.
Key Facts
- PMID
- 30450689
- Journal
- Phytotherapy research : PTR
- Year
- 2019
- Study type
- Randomized Controlled Trial
- Authors
- Papada E et al. (7 authors)
- DOI
- 10.1002/ptr.6229
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Copper (Supplement), published as a randomized controlled trial.
The purpose of this study was to explore the effect of mastiha supplement, rich in bioactive nutraceuticals, in active inflammatory bowel disease.
Why It Was Studied
There is a keen research upon the effects of nutraceuticals on inflammatory bowel disease.
A clinically important difference between groups in IBDQ was defined as primary outcome.
Who Took Part
The abstract describes 60 patients taking part.
PubMed tags the participants as both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The patients were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.
Neither the patients nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.
Medical and dietary history, Inflammatory Bowel Disease Questionnaire (IBDQ), Harvey-Bradshaw index, partial Mayo score, biochemical indices, faecal, and blood inflammatory markers were assessed.
What Was Measured
A clinically important difference between groups in IBDQ was defined as primary outcome.
PubMed files the paper under topics including Biomarkers, Dietary Supplements, Feces, Inflammatory Bowel Diseases, Lactoferrin, Pistacia and Surveys and Questionnaires.
Author keywords: Crohn's disease, lysozyme, mastiha (Pistacia lentiscus), nutraceuticals and ulcerative colitis.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 60 patients.
The publication is from 2019 (Phytotherapy research : PTR), a journal based in England.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.